NextGen Healthcare announces CEO transition

NextGen Healthcare, a California-based electronic health record company and provider of ambulatory-focused technology services, and its president and CEO, Rusty Frantz, have reached a mutual agreement for Frantz to step down from his role, effective immediately. 

In addition, Frantz will no longer serve as a member of the board of directors. An executive leadership committee has already been established to temporarily lead the company and search for a new leader, and several executives are sitting on the search committee.

The committee will also work with a newly established board oversight committee, which includes independent directors Jeff Margolis, non-executive chairman of the board, and Craig Barbarosh, vice chairman of the board.

“On behalf of the Board, we thank Rusty for leading NextGen Healthcare through a successful operational reinvention,” Margolis said in a statement. “Today, the company benefits from the highest-quality solution offerings in ambulatory healthcare, best-in-class customer service and satisfaction levels, and an exceptionally engaged team of executives and employees who daily live a culture that believes in better. We wish Rusty the best.”

The company also affirmed its outlook for fiscal year 2022, projecting revenue between $574 million and $584 million.

The announcement of the executive shakeup comes just four weeks after NextGen named Srinivas (Sri) Velamoor as its chief growth officer, a new position for the company.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.